| Nome |
# |
|
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas, file e268c4ca-bf91-a6b7-e053-3a05fe0adea1
|
801
|
|
Fasting-mimicking diet and hormone therapy induce breast cancer regression, file 1602dfb4-1f6a-4ed0-ba22-bfdef1c97c9d
|
296
|
|
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia, file e268c4ca-ba16-a6b7-e053-3a05fe0adea1
|
250
|
|
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair., file e268c4c9-bf2c-a6b7-e053-3a05fe0adea1
|
240
|
|
Sirt6 regulates dendritic cell differentiation, maturation, and function, file e268c4c7-989f-a6b7-e053-3a05fe0adea1
|
117
|
|
Nutrients in the Prevention of Alzheimer's Disease, file e268c4cb-4328-a6b7-e053-3a05fe0adea1
|
110
|
|
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival, file e268c4ca-62b7-a6b7-e053-3a05fe0adea1
|
109
|
|
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition., file e268c4ca-0d6f-a6b7-e053-3a05fe0adea1
|
105
|
|
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs, file e268c4cb-4326-a6b7-e053-3a05fe0adea1
|
99
|
|
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8, file e268c4c9-cdb5-a6b7-e053-3a05fe0adea1
|
95
|
|
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition, file e268c4c9-ae5e-a6b7-e053-3a05fe0adea1
|
88
|
|
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation, file e268c4ca-6bb9-a6b7-e053-3a05fe0adea1
|
79
|
|
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach, file e268c4ca-eb89-a6b7-e053-3a05fe0adea1
|
75
|
|
Biological Insights into Myeloma and Other B Cell Malignancies, file e268c4ca-3493-a6b7-e053-3a05fe0adea1
|
71
|
|
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells, file e268c4cb-477d-a6b7-e053-3a05fe0adea1
|
66
|
|
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis, file e268c4c7-3f1b-a6b7-e053-3a05fe0adea1
|
65
|
|
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma, file e268c4c6-ca01-a6b7-e053-3a05fe0adea1
|
57
|
|
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications, file e268c4c6-cf87-a6b7-e053-3a05fe0adea1
|
53
|
|
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells, file e268c4cf-0b27-a6b7-e053-3a05fe0adea1
|
46
|
|
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent, file e268c4cc-9070-a6b7-e053-3a05fe0adea1
|
42
|
|
Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model, file e268c4cc-5ff2-a6b7-e053-3a05fe0adea1
|
21
|
|
Radiomics and artificial intelligence analysis of CT data for the
identification of prognostic features in multiple myeloma, file e268c4cc-218c-a6b7-e053-3a05fe0adea1
|
19
|
|
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma, file e268c4ca-dc2c-a6b7-e053-3a05fe0adea1
|
11
|
|
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery, file 7b43c5ca-86d8-437f-a42a-4be284108c9d
|
8
|
|
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment, file e268c4ca-4caa-a6b7-e053-3a05fe0adea1
|
8
|
|
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells, file e268c4ce-349a-a6b7-e053-3a05fe0adea1
|
8
|
|
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents, file e268c4ca-8944-a6b7-e053-3a05fe0adea1
|
7
|
|
Radiomics and artificial intelligence for outcome prediction in multiple myeloma patients undergoing autologous transplantation: A feasibility study with ct data, file e268c4ce-5c35-a6b7-e053-3a05fe0adea1
|
7
|
|
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells, file 90274659-2248-4db2-a2d9-8e3628c61b91
|
6
|
|
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information, file e268c4ca-235e-a6b7-e053-3a05fe0adea1
|
6
|
|
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice, file e268c4cd-7452-a6b7-e053-3a05fe0adea1
|
6
|
|
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study, file e268c4ce-6f67-a6b7-e053-3a05fe0adea1
|
5
|
|
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma, file e268c4cd-2fe5-a6b7-e053-3a05fe0adea1
|
4
|
|
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells, file e268c4cd-90b9-a6b7-e053-3a05fe0adea1
|
4
|
|
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells., file e268c4c5-fb8c-a6b7-e053-3a05fe0adea1
|
3
|
|
Targeting Inflammation in Primary Cardiovascular Prevention, file e268c4ca-9288-a6b7-e053-3a05fe0adea1
|
3
|
|
null, file e268c4ca-efa4-a6b7-e053-3a05fe0adea1
|
3
|
|
The non-coding RNA landscape of plasma cell dyscrasias, file e268c4cc-58dd-a6b7-e053-3a05fe0adea1
|
3
|
|
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma, file d9224a5a-a42e-4d62-a701-4dbb6541b820
|
2
|
|
Evaluation of prognostic indices in elderly hospitalized patients, file e268c4ca-12a2-a6b7-e053-3a05fe0adea1
|
2
|
|
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma, file e268c4ca-2c87-a6b7-e053-3a05fe0adea1
|
2
|
|
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells, file e268c4cc-56b4-a6b7-e053-3a05fe0adea1
|
2
|
|
Fasting-mimicking diet and hormone therapy induce breast cancer regression, file e268c4cd-1080-a6b7-e053-3a05fe0adea1
|
2
|
|
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment, file e268c4ce-5ee8-a6b7-e053-3a05fe0adea1
|
2
|
|
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients, file 20d2957f-818c-4f33-b8dc-cab98fe463c6
|
1
|
|
Harnessing Immune Response in Acute Myeloid Leukemia, file b632d7ff-f43e-4667-a221-b5bfa3b8ac95
|
1
|
|
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells., file e268c4c6-078d-a6b7-e053-3a05fe0adea1
|
1
|
|
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response, file e268c4c9-a2da-a6b7-e053-3a05fe0adea1
|
1
|
|
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin., file e268c4c9-c8aa-a6b7-e053-3a05fe0adea1
|
1
|
|
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells, file e268c4ca-4360-a6b7-e053-3a05fe0adea1
|
1
|
|
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects, file e268c4ca-650d-a6b7-e053-3a05fe0adea1
|
1
|
|
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies, file e268c4ca-6841-a6b7-e053-3a05fe0adea1
|
1
|
|
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells, file e268c4ca-7f8d-a6b7-e053-3a05fe0adea1
|
1
|
|
Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach, file e268c4cb-54d1-a6b7-e053-3a05fe0adea1
|
1
|
|
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status, file e268c4cd-6ab8-a6b7-e053-3a05fe0adea1
|
1
|
|
The non-coding RNA landscape of plasma cell dyscrasias, file fd25ee75-80d2-4f10-be56-925e9302af22
|
1
|
| Totale |
3.020 |